HemaSphere



P1120 THE EFFICACY AND SAFETY OF ZANUBRUTINIB AND DEXAMETHASONE IN SYMPTOMATIC WALDENSTROM MACROGLOBULINNEMIA

Topic: 18. Indolent and mantle-cell non-Hodgkin lymphoma - Clinical

Aijun Liu¹, Jiahui Yin¹, Jin Lu², Yanping Ma³, Da Gao⁴, Luoming Hua⁵, Yin Tian¹, Yuan Jian¹, Wenming Chen¹

¹ Beijing Chaoyang Hospital, affiliated to Capital Medical University, Beijing, China;² Peking University People's Hospital, Beijing, China;³ Second hospital of Shanxi Medical University, Taiyuan, China;⁴ The Affiliated Hospital of Inner Mongolia Medical University, Huhehaote, China;⁵ Affiliated Hospital of Hebei University, Shijiazhuang, China

Background: Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM) But the efficacy of single drug is limited.

Aims: This single arm study (ChiCTR2000038140) evaluated the efficacy and safety of the combination of zanubrutinib, a novel, highly selective BTK inhibitor, and dexamethasone in patients with WM.

Methods: Symptomatic patients with WM were enrolled to the regimen of zanubrutinib and dexamethasone (ZD)*. The primary endpoint was objective response rate (ORR), progression-free survival (PFS). Key secondary endpoints included the proportion of patients achieving a complete or very good partial response (CR or VGPR), duration of response (DOR), Time to response (TOR), disease burden, and safety. The control group** were matched patients treated by chemotherapy or immunechemotherapy previously in Beijing Chaoyang Hospital.

Results: A total of 22 Patients with WM were enrolled in this study, median age 67(36-89); 68.2% males, 12 patients were untreated, others were treated patients. IPSS assessment grade1 23.8%; grade2 19.0%; grade3 57.2%. 90.9% (20/22) patients with MYD88L265P mutation, 27.3% (3/11) patients with CXCR4 mutation.

21 patients received ≥ 1 dose of study treatment. Median follow-up of 8.2 months, median DOR and PFS were not reached; 95% of patients were progression-free at 6 months. ORR was 95% in those (17/18) received ZD regimen more than 2 months. No patient achieved a CR. 33.3% of patients in ZD group achieved a VGPR, time to VGPR within 3 months in 57.1% of patients⊠a statistically significant difference with control group (0%, P = 0.001). Time to PR in ZD group was 2 months, much faster than control group (11 months) (P = 0.023) by K-M analysis.

The study-safety profile was consistent with previous BTK inhibitor clinical trial data. 45% of patients had any grade AEs. In which, the most frequent grade <=2 AEs were hemorrhage(18.2% all grade 1), rash(9.1%), hyperglycemia (13.6%), infection(9.1%), nausea and vomiting (9.1%), hypogammaglobulinemia(4.5%), neutropenia(9.1%). Grade 3/4 AEs were atrial fibrillation(4.5%), leading to treatment discontinuation. Other cause of treatment discontinuation is hyperglycemia, bowel obstruction by disease.

Comments

*The regimen of ZD : Zanubrutinib 240mg d1-28, dexamethasone 20mg D1-4,15-18. Patients more than 75 years old, Zanubrutinib 160mg d1-28, dexamethasone 10mg D1-4,15-18. After 8 cycle, Zanubrutinib use as maintenance.

** The control group: 22 treated patients with WM, median age 69.5(39-84); 68.2% males. IPSS Grade1 21.4%; Grade2 32.1%; Grade3 42.9%; Unknown 3.6%. 75% (9/12) patients with MYD88L265P mutation, 33% (1/3) patients with CXCR4 mutation. Treatment included chemotherapy(containing nitrogen mustard phenylbutyrate, fludarabine, cyclophosphamide), proteasome inhibitor regimens, rituximab regimens and immunomodulator regimens.

Summary/Conclusion: These results demonstrate that zanubrutinib and dexamethasone are quickly effective in the

Copyright Information: (Online) ISSN: 2572-9241

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.

^{© 2022} the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.





treatment of WM, with more deeper response and less toxicity.

Copyright Information: (Online) ISSN: 2572-9241

© 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.

Abstract Book Citations: Authors, Title, HemaSphere, 2022;6:(S3):pages. The individual abstract DOIs can be found at https://journals.lww.com/hemasphere/pages/default.aspx.

Disclaimer: Articles published in the journal HemaSphere exclusively reflect the opinions of the authors. The authors are responsible for all content in their abstracts including accuracy of the facts, statements, citing resources, etc.